- Home
- CRGX vs SCPH Comparison
CRGX vs SCPH Comparison
Compare CRGX & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- SCPH
- Stock Information
- Founded
- CRGX 2021
- SCPH 2013
- Country
- CRGX United States
- SCPH United States
- Employees
- CRGX N/A
- SCPH N/A
- Industry
- CRGX
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- CRGX
- SCPH Health Care
- Exchange
- CRGX Nasdaq
- SCPH Nasdaq
- Market Cap
- CRGX 180.4M
- SCPH 173.6M
- IPO Year
- CRGX 2023
- SCPH 2017
- Fundamental
- Price
- CRGX $4.23
- SCPH $2.50
- Analyst Decision
- CRGX Hold
- SCPH Strong Buy
- Analyst Count
- CRGX 7
- SCPH 3
- Target Price
- CRGX $4.67
- SCPH $14.00
- AVG Volume (30 Days)
- CRGX 824.1K
- SCPH 637.9K
- Earning Date
- CRGX 05-13-2025
- SCPH 03-19-2025
- Dividend Yield
- CRGX N/A
- SCPH N/A
- EPS Growth
- CRGX N/A
- SCPH N/A
- EPS
- CRGX N/A
- SCPH N/A
- Revenue
- CRGX N/A
- SCPH $36,332,000.00
- Revenue This Year
- CRGX $64.32
- SCPH $134.20
- Revenue Next Year
- CRGX N/A
- SCPH $99.40
- P/E Ratio
- CRGX N/A
- SCPH N/A
- Revenue Growth
- CRGX N/A
- SCPH 167.28
- 52 Week Low
- CRGX $3.00
- SCPH $2.21
- 52 Week High
- CRGX $25.45
- SCPH $5.65
- Technical
- Relative Strength Index (RSI)
- CRGX 44.99
- SCPH 32.57
- Support Level
- CRGX $3.99
- SCPH $2.87
- Resistance Level
- CRGX $4.25
- SCPH $3.08
- Average True Range (ATR)
- CRGX 0.21
- SCPH 0.21
- MACD
- CRGX 0.14
- SCPH -0.05
- Stochastic Oscillator
- CRGX 57.89
- SCPH 29.96
Stock Price Comparison Chart: CRGX vs SCPH
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.